148 related articles for article (PubMed ID: 36323434)
1. Intravenous administration of viral vectors expressing prostate cancer antigens enhances the magnitude and functionality of CD8+ T cell responses.
Vardeu A; Davis C; McDonald I; Stahlberg G; Thapa B; Piotrowska K; Marshall MA; Evans T; Wheeler V; Sebastian S; Anderson K
J Immunother Cancer; 2022 Nov; 10(11):. PubMed ID: 36323434
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial.
Cappuccini F; Bryant R; Pollock E; Carter L; Verrill C; Hollidge J; Poulton I; Baker M; Mitton C; Baines A; Meier A; Schmidt G; Harrop R; Protheroe A; MacPherson R; Kennish S; Morgan S; Vigano S; Romero PJ; Evans T; Catto J; Hamdy F; Hill AVS; Redchenko I
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32591433
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer.
Cappuccini F; Stribbling S; Pollock E; Hill AV; Redchenko I
Cancer Immunol Immunother; 2016 Jun; 65(6):701-13. PubMed ID: 27052571
[TBL] [Abstract][Full Text] [Related]
4. 5T4 oncofoetal glycoprotein: an old target for a novel prostate cancer immunotherapy.
Cappuccini F; Pollock E; Stribbling S; Hill AVS; Redchenko I
Oncotarget; 2017 Jul; 8(29):47474-47489. PubMed ID: 28537896
[TBL] [Abstract][Full Text] [Related]
5. Immunization with recombinant DNA and modified vaccinia virus Ankara (MVA) vectors delivering PSCA and STEAP1 antigens inhibits prostate cancer progression.
Krupa M; Canamero M; Gomez CE; Najera JL; Gil J; Esteban M
Vaccine; 2011 Feb; 29(7):1504-13. PubMed ID: 21182993
[TBL] [Abstract][Full Text] [Related]
6. Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.
Kolibab K; Yang A; Derrick SC; Waldmann TA; Perera LP; Morris SL
Clin Vaccine Immunol; 2010 May; 17(5):793-801. PubMed ID: 20357059
[TBL] [Abstract][Full Text] [Related]
7. Heterologous prime-boost vaccination targeting MAGE-type antigens promotes tumor T-cell infiltration and improves checkpoint blockade therapy.
McAuliffe J; Chan HF; Noblecourt L; Ramirez-Valdez RA; Pereira-Almeida V; Zhou Y; Pollock E; Cappuccini F; Redchenko I; Hill AV; Leung CSK; Van den Eynde BJ
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479921
[TBL] [Abstract][Full Text] [Related]
8. Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.
Green CA; Sande CJ; Scarselli E; Capone S; Vitelli A; Nicosia A; Silva-Reyes L; Thompson AJ; de Lara CM; Taylor KS; Haworth K; Hutchings CL; Cargill T; Angus B; Klenerman P; Pollard AJ
J Infect; 2019 May; 78(5):382-392. PubMed ID: 30742894
[TBL] [Abstract][Full Text] [Related]
9. Modified Vaccinia Virus Ankara Can Induce Optimal CD8
Wong YC; Croft S; Smith SA; Lin LCW; Cukalac T; La Gruta NL; Drexler I; Tscharke DC
J Virol; 2019 Nov; 93(21):. PubMed ID: 31375596
[TBL] [Abstract][Full Text] [Related]
10. Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV.
Marín MQ; Pérez P; Ljungberg K; Sorzano CÓS; Gómez CE; Liljeström P; Esteban M; García-Arriaza J
J Virol; 2019 Apr; 93(7):. PubMed ID: 30674625
[TBL] [Abstract][Full Text] [Related]
11. Deletion of the vaccinia virus N2L gene encoding an inhibitor of IRF3 improves the immunogenicity of modified vaccinia virus Ankara expressing HIV-1 antigens.
García-Arriaza J; Gómez CE; Sorzano CÓ; Esteban M
J Virol; 2014 Mar; 88(6):3392-410. PubMed ID: 24390336
[TBL] [Abstract][Full Text] [Related]
12. A heterologous prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for hepatitis C virus.
Fournillier A; Frelin L; Jacquier E; Ahlén G; Brass A; Gerossier E; Holmström F; Broderick KE; Sardesai NY; Bonnefoy JY; Inchauspé G; Sällberg M
J Infect Dis; 2013 Sep; 208(6):1008-19. PubMed ID: 23776192
[TBL] [Abstract][Full Text] [Related]
13. TLR1/2 activation during heterologous prime-boost vaccination (DNA-MVA) enhances CD8+ T Cell responses providing protection against Leishmania (Viannia).
Jayakumar A; Castilho TM; Park E; Goldsmith-Pestana K; Blackwell JM; McMahon-Pratt D
PLoS Negl Trop Dis; 2011 Jun; 5(6):e1204. PubMed ID: 21695103
[TBL] [Abstract][Full Text] [Related]
14. Heterologous prime-boost regimens with a recombinant chimpanzee adenoviral vector and adjuvanted F4 protein elicit polyfunctional HIV-1-specific T-Cell responses in macaques.
Lorin C; Vanloubbeeck Y; Baudart S; Ska M; Bayat B; Brauers G; Clarinval G; Donner MN; Marchand M; Koutsoukos M; Mettens P; Cohen J; Voss G
PLoS One; 2015; 10(4):e0122835. PubMed ID: 25856308
[TBL] [Abstract][Full Text] [Related]
15. Dual antigen target-based immunotherapy for prostate cancer eliminates the growth of established tumors in mice.
Karan D; Dubey S; Van Veldhuizen P; Holzbeierlein JM; Tawfik O; Thrasher JB
Immunotherapy; 2011 Jun; 3(6):735-46. PubMed ID: 21668311
[TBL] [Abstract][Full Text] [Related]
16. Adenovirus vector-based prime-boost vaccination via heterologous routes induces cervicovaginal CD8
Çuburu N; Khan S; Thompson CD; Kim R; Vellinga J; Zahn R; Lowy DR; Scheper G; Schiller JT
Int J Cancer; 2018 Apr; 142(7):1467-1479. PubMed ID: 29159802
[TBL] [Abstract][Full Text] [Related]
17. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
[TBL] [Abstract][Full Text] [Related]
18. Qualitative differences in cellular immunogenicity elicited by hepatitis C virus T-Cell vaccines employing prime-boost regimens.
Tan WG; Zubkova I; Kachko A; Wells F; Adler H; Sutter G; Major ME
PLoS One; 2017; 12(7):e0181578. PubMed ID: 28732046
[TBL] [Abstract][Full Text] [Related]
19. Improving recombinant MVA immune responses: potentiation of the immune responses to HIV-1 with MVA and DNA vectors expressing Env and the cytokines IL-12 and IFN-gamma.
Abaitua F; Rodríguez JR; Garzón A; Rodríguez D; Esteban M
Virus Res; 2006 Mar; 116(1-2):11-20. PubMed ID: 16214252
[TBL] [Abstract][Full Text] [Related]
20. Heterologous prime-boost-boost immunisation of Chinese cynomolgus macaques using DNA and recombinant poxvirus vectors expressing HIV-1 virus-like particles.
Bridge SH; Sharpe SA; Dennis MJ; Dowall SD; Getty B; Anson DS; Skinner MA; Stewart JP; Blanchard TJ
Virol J; 2011 Sep; 8():429. PubMed ID: 21899739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
